Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.52 |
| ▸ | CDK8 | P49336 | 2/20 | 0.49 |
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13772472 | 1.00 | MAPK14 (0.55) | MAPK14MAPTLMNAMAPK11MAPK13 | |
| SCHEMBL13772474 | 1.00 | MAPK14 (0.55) | MAPK14MAPTLMNAMAPK11MAPK13 | |
| SCHEMBL4138182 | 1.00 | MAPK14 (0.55) | MAPK14MAPTLMNAMAPK11MAPK13 | |
| SCHEMBL4130326 | 1.00 | MAPK14 (0.55) | MAPK14MAPTLMNAMAPK11MAPK13 | |
| SCHEMBL13772470 | 1.00 | MAPK14 (0.55) | MAPK14MAPTLMNAMAPK11MAPK13 | |
| SCHEMBL4138490 | 1.00 | MAPK14 (0.55) | MAPK14MAPTLMNAMAPK11MAPK13 | |
| SCHEMBL4141675 | 1.00 | MAPK14 (0.55) | MAPK14MAPTLMNAMAPK11MAPK13 | |
| SCHEMBL4138250 | 0.95 | MAPK14 (0.57) | MAPK14MAPTLMNAMAPK11MAPK13 | |
| SCHEMBL4132120 | 0.88 | CDK8 (0.47) | MAPK14MAPK11MAPK13MAPK12CDK8 | |
| SCHEMBL4137645 | 0.83 | MEN1 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | PGLS, TFPI, Q6ZSR9 | MAPK14 1554/4885MAPT 3184/4885LMNA 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.